BEVACIZUMAB + PEMBROLIZUMAB + Izalontamab Brengitecan for uterine cervical neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 Jul 2025: Trial registered, NCT07054567
  2. 21 Aug 2025: Trial started, NCT07054567

The trials

NCT07054567: A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer

State
Under way
Phase
Phase 2
People
96 planned
Started
21 Aug 2025
Primary completion
May 2027
Arms
BL-B01D1 + pembrolizumab ± bevacizumab
Results
None posted
  1. 8 Jul 2025: Trial registered
  2. 21 Aug 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.